Posted by Michael Wonder on 10 Jun 2021
Biogen’s new Alzheimer’s drug could cost Medicare billions of dollars a year, report finds
10 June 2021 - “If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s expectations, spending on Aduhelm alone would exceed $57 billion” a year, the group said, “far surpassing spending on all other Part B-covered drugs combined.”
Biogen’s pricy new Alzheimer’s drug, Aduhelm, could cost Medicare billions of dollars a year, according to an analysis published Thursday by the nonprofit Kaiser Family Foundation.
